No Data
No Data
Eli Lilly's Stock Selloff Is Overdone, Analysts Say. Here's Why.
Express News | UBS Maintains Neutral on Amgen, Lowers Price Target to $315
Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data
Express News | RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $320
Amgen | 10-Q: Q1 2025 Earnings Report
Amgen Analyst Ratings